Lauren M Jansson1, Martha L Velez2, Krystle McConnell2, Nancy Spencer3, Michelle Tuten4, Hendree Jones5, Rebeca Rios2, Van L King2, Neeraj Gandotra2, Lorraine Millio2, Janet A DiPietro6. 1. Johns Hopkins University School of Medicine, Baltimore, MD, United States. Electronic address: ljansson@jhmi.edu. 2. Johns Hopkins University School of Medicine, Baltimore, MD, United States. 3. Johns Hopkins Bayview Medical Center, Baltimore, MD, United States. 4. University of Maryland, School of Social Work, MD, United States. 5. University of North Carolina Chapel Hill, Chapel Hill, NC, United States. 6. Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States.
Abstract
BACKGROUND AND OBJECTIVES: Maternal buprenorphine maintenance predisposes the infant to exhibit neonatal abstinence syndrome (NAS), but there is insufficient published information regarding the nature of NAS and factors that contribute to its severity in buprenorphine-exposed infants. METHODS: The present study evaluated forty-one infants of buprenorphine-maintained women in comprehensive substance use disorder treatment who participated in an open-label study examining the effects of maternal buprenorphine maintenance on infant outcomes. Modifiers of the infant outcomes, including maternal treatment and substance use disorder parameters, were also evaluated. RESULTS: Fifty-nine percent of offspring exhibited NAS that required pharmacologic management. Both maternal buprenorphine dose as well as prenatal polysubstance exposure to illicit substance use/licit substance misuse were independently associated with NAS expression. Polysubstance exposure was associated with more severe NAS expression after controlling for the effects of buprenorphine dose. Other exposures, including cigarette smoking and SRI use, were not related to outcomes. Maternal buprenorphine dose was positively associated with lower birth weight and length. CONCLUSIONS: Polysubstance exposure was the most potent predictor of NAS severity in this sample of buprenorphine-exposed neonates. This finding suggests the need for interventions that reduce maternal polysubstance use during medication assisted treatment for opioid use disorder, and highlights the necessity of a comprehensive approach, beyond buprenorphine treatment alone, for the optimal care for pregnant women with opioid use disorders.
BACKGROUND AND OBJECTIVES: Maternal buprenorphine maintenance predisposes the infant to exhibit neonatal abstinence syndrome (NAS), but there is insufficient published information regarding the nature of NAS and factors that contribute to its severity in buprenorphine-exposed infants. METHODS: The present study evaluated forty-one infants of buprenorphine-maintained women in comprehensive substance use disorder treatment who participated in an open-label study examining the effects of maternal buprenorphine maintenance on infant outcomes. Modifiers of the infant outcomes, including maternal treatment and substance use disorder parameters, were also evaluated. RESULTS: Fifty-nine percent of offspring exhibited NAS that required pharmacologic management. Both maternal buprenorphine dose as well as prenatal polysubstance exposure to illicit substance use/licit substance misuse were independently associated with NAS expression. Polysubstance exposure was associated with more severe NAS expression after controlling for the effects of buprenorphine dose. Other exposures, including cigarette smoking and SRI use, were not related to outcomes. Maternal buprenorphine dose was positively associated with lower birth weight and length. CONCLUSIONS: Polysubstance exposure was the most potent predictor of NAS severity in this sample of buprenorphine-exposed neonates. This finding suggests the need for interventions that reduce maternal polysubstance use during medication assisted treatment for opioid use disorder, and highlights the necessity of a comprehensive approach, beyond buprenorphine treatment alone, for the optimal care for pregnant women with opioid use disorders.
Authors: Elizabeth E Krans; Debra Bogen; Gale Richardson; Seo Young Park; Shannon L Dunn; Nancy Day Journal: Subst Abus Date: 2016-02-25 Impact factor: 3.716
Authors: Hendrée E Jones; Karol Kaltenbach; Sarah H Heil; Susan M Stine; Mara G Coyle; Amelia M Arria; Kevin E O'Grady; Peter Selby; Peter R Martin; Gabriele Fischer Journal: N Engl J Med Date: 2010-12-09 Impact factor: 91.245
Authors: Stephen W Patrick; Robert E Schumacher; Brian D Benneyworth; Elizabeth E Krans; Jennifer M McAllister; Matthew M Davis Journal: JAMA Date: 2012-04-30 Impact factor: 56.272
Authors: Jean Y Ko; Stephen W Patrick; Van T Tong; Roshni Patel; Jennifer N Lind; Wanda D Barfield Journal: MMWR Morb Mortal Wkly Rep Date: 2016-08-12 Impact factor: 17.586
Authors: Rishi J Desai; Krista F Huybrechts; Sonia Hernandez-Diaz; Helen Mogun; Elisabetta Patorno; Karol Kaltenbach; Leslie S Kerzner; Brian T Bateman Journal: BMJ Date: 2015-05-14
Authors: Jillian Laslo; Jon-Michael Brunner; Daniel Burns; Emily Butler; Autumn Cunningham; Ryan Killpack; Courtney Pyeritz; Kimberly Rinard; Jennifer Childers; Joseph Horzempa Journal: Matern Health Neonatol Perinatol Date: 2017-02-10
Authors: Zana Percy; Cole Brokamp; Jennifer M McAllister; Patrick Ryan; Scott L Wexelblatt; Eric S Hall Journal: J Pediatr Date: 2020-05-15 Impact factor: 4.406
Authors: Brittany L Smith; Eric S Hall; Jennifer M McAllister; Michael P Marcotte; Kenneth D R Setchell; Vandana Megaraj; Kristine L Jimenez; T John Winhusen; Scott L Wexelblatt Journal: J Perinatol Date: 2022-02-17 Impact factor: 3.225
Authors: Kimberly Page; Cristina Murray-Krezan; Lawrence Leeman; Mary Carmody; Julia M Stephen; Ludmila N Bakhireva Journal: Addict Sci Clin Pract Date: 2022-01-06